![Patrick Rivers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Rivers
Private Equity Investor bij
aMoon Ventures Y Sh Ltd.
Profiel
Patrick Rivers worked at XOMA Royalty Corp.
as a Process Development Associate in 2009.
Mr. Rivers worked at Exelixis, Inc. as an Associate Research Scientist in 2011.
Mr. Rivers worked at Sutro Biopharma, Inc. as a Senior Research Associate in 2014.
Mr. Rivers worked at Aquilo Capital Management LLC from 2014 to 2024, serving as Managing Director & Head of Research from 2019 to 2024.
Mr. Rivers completed an undergraduate degree at the University of California, Los Angeles in 2005.
Mr. Rivers earned an MBA from Haas School of Business in 2016.
Actieve functies van Patrick Rivers
| Bedrijven | Functie | Begin |
|---|---|---|
aMoon Ventures Y Sh Ltd.
 aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures invests in companies located in Israel. The firm focuses on life-sciences, biopharma, digital health and medical technology companies. It provides financing for early and late stage capital requirements with an investment size of USD 10 - 30 million. The firm makes follow-on investments and also acts as lead investor. | Private Equity Investor | 01-08-2024 |
Eerdere bekende functies van Patrick Rivers
| Bedrijven | Functie | Einde |
|---|---|---|
Aquilo Capital Management LLC
 Aquilo Capital Management LLC Investment ManagersFinance Aquilo manages funds that generally focus on the life sciences industry, with a specific focus on biotechnology and drug discovery and development companies. The firm employs deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. Their goal is to provide long- term clients and investors with a high rate of return relative to risk over time. | Directeur van Onderzoek - Eigen Vermogen | 01-08-2024 |
| SUTRO BIOPHARMA, INC. | Corporate Officer/Principal | 01-06-2014 |
| EXELIXIS, INC. | Corporate Officer/Principal | 01-01-2011 |
| XOMA ROYALTY CORPORATION | Corporate Officer/Principal | 01-01-2009 |
Opleiding van Patrick Rivers
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
98
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Sutro Biopharma, Inc.
 Sutro Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops new products in protein vaccines and therapeutics | Health Technology |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Haas School of Business
 Haas School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aquilo Capital Management LLC
Aquilo Capital Management LLC Investment ManagersFinance Aquilo manages funds that generally focus on the life sciences industry, with a specific focus on biotechnology and drug discovery and development companies. The firm employs deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. Their goal is to provide long- term clients and investors with a high rate of return relative to risk over time. | Finance |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures invests in companies located in Israel. The firm focuses on life-sciences, biopharma, digital health and medical technology companies. It provides financing for early and late stage capital requirements with an investment size of USD 10 - 30 million. The firm makes follow-on investments and also acts as lead investor. | Finance |
